Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 45pembrolizumab 40Magnetic Resonance Spectroscopy 32Cyclophosphamide 31Biopsy 31fludarabine 27Cetuximab 19Cisplatin 18Carboplatin 18atezolizumab 15Bevacizumab 15Fluorouracil 14venetoclax 13Radiation 13Leucovorin 13fludarabine phosphate 12Radiotherapy 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Nivolumab 11Cytarabine 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Irinotecan 9Fulvestrant 9Radiosurgery 8Platinum 8Immunoglobulin G 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Immunotherapy × 30 days × Clear all
NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Suspended
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡